Connection
Jennifer Dotson to Biosimilar Pharmaceuticals
This is a "connection" page, showing publications Jennifer Dotson has written about Biosimilar Pharmaceuticals.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.609 |
|
|
|
-
McNicol M, Abdel-Rasoul M, McClinchie MG, Morris GA, Boyle B, Dotson JL, Michel HK, Maltz RM. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024 03; 78(3):644-652.
Score: 0.220
-
Yossef L, Wright M, Benedict J, Morris GA, McNicol M, Boyle B, Dotson JL, Michel HK, Maltz RM. Patient and Caregivers' Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2022 07 01; 75(1):59-63.
Score: 0.194
-
Morris GA, McNicol M, Boyle B, Donegan A, Dotson J, Michel HK, Maltz RM. Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money. Inflamm Bowel Dis. 2022 03 30; 28(4):531-538.
Score: 0.194